Metabotropic	metabotropic	O	O	O	O
glutamate	glutamate	CHEMICALS	O	OTHERS	I
7	7	O	O	O	O
receptor	receptor	O	O	O	O
subtype	subtype	O	O	O	O
modulates	modulates	O	O	O	O
motor	motor	O	O	O	O
symptoms	symptoms	O	O	O	O
in	in	O	O	O	O
rodent	rodent	O	O	O	O
models	models	O	O	O	O
of	of	O	O	O	O
Parkinson	parkinson	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Metabotropic	metabotropic	O	O	O	O
glutamate	glutamate	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
mGlu	mglu	O	O	O	O
)	)	O	O	O	O
receptors	receptors	O	O	O	O
modulate	modulate	O	O	O	O
synaptic	synaptic	O	O	O	O
transmission	transmission	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
central	central	O	O	O	O
nervous	nervous	O	O	O	O
system	system	O	O	O	O
and	and	O	O	O	O
represent	represent	O	O	O	O
promising	promising	O	O	O	O
therapeutic	therapeutic	O	O	O	O
targets	targets	O	O	O	O
for	for	O	O	O	O
symptomatic	symptomatic	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
Parkinson	parkinson	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
(	(	O	O	O	O
PD	pd	O	DISEASE	OTHERS	I
)	)	O	O	O	O
.	.	O	O	O	O

Among	among	O	O	O	O
the	the	O	O	O	O
eight	eight	O	O	O	O
mGlu	mglu	O	O	O	O
receptor	receptor	O	O	O	O
subtypes	subtypes	O	O	O	O
,	,	O	O	O	O
mGlu7	mglu7	O	O	O	O
receptor	receptor	O	O	O	O
is	is	O	O	O	O
prominently	prominently	O	O	O	O
expressed	expressed	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
basal	basal	O	O	O	O
ganglia	ganglia	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
its	its	O	O	O	O
role	role	O	O	O	O
in	in	O	O	O	O
restoring	restoring	O	O	O	O
motor	motor	O	O	O	O
function	function	O	O	O	O
in	in	O	O	O	O
animal	animal	O	O	O	O
models	models	O	O	O	O
of	of	O	O	O	O
PD	pd	O	DISEASE	OTHERS	I
is	is	O	O	O	O
not	not	O	O	O	O
known	known	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
N	n	O	O	OTHERS	I
,	,	O	O	OTHERS	I
N'-dibenzhydrylethane-1,2-diamine	n'-dibenzhydrylethane-1,2-diamine	O	O	OTHERS	I
dihydrochloride	dihydrochloride	O	O	OTHERS	I
(	(	O	O	O	O
AMN082	amn082	O	O	OTHERS	I
)	)	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
selective	selective	O	O	O	O
allosteric	allosteric	O	O	O	O
activator	activator	O	O	O	O
of	of	O	O	O	O
mGlu7	mglu7	O	O	O	O
receptors	receptors	O	O	O	O
,	,	O	O	O	O
were	were	O	O	O	O
thus	thus	O	O	O	O
tested	tested	O	O	O	O
in	in	O	O	O	O
different	different	O	O	O	O
rodent	rodent	O	O	O	O
models	models	O	O	O	O
of	of	O	O	O	O
PD	pd	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Here	here	O	O	O	O
,	,	O	O	O	O
we	we	O	O	O	O
show	show	O	O	O	O
that	that	O	O	O	O
oral	oral	O	O	O	O
(	(	O	O	O	O
5	5	O	O	O	O
mg/kg	mg/kg	O	O	O	O
)	)	O	O	O	O
or	or	O	O	O	O
intrastriatal	intrastriatal	O	O	O	O
administration	administration	O	O	O	O
(	(	O	O	O	O
0.1	0.1	O	O	O	O
and	and	O	O	O	O
0.5	0.5	O	O	O	O
nmol	nmol	O	O	O	O
)	)	O	O	O	O
of	of	O	O	O	O
AMN082	amn082	O	O	OTHERS	I
reverses	reverses	O	O	O	O
haloperidol-induced	haloperidol-induced	O	O	O	O
catalepsy	catalepsy	O	DISEASE	OTHERS	I
in	in	O	O	O	O
rats	rats	O	O	O	O
.	.	O	O	O	O

AMN082	amn082	O	O	OTHERS	I
(	(	O	O	O	O
2.5	2.5	O	O	O	O
and	and	O	O	O	O
5	5	O	O	O	O
mg/kg	mg/kg	O	O	O	O
)	)	O	O	O	O
reduces	reduces	O	O	O	O
apomorphine-induced	apomorphine-induced	O	O	O	O
rotations	rotations	O	O	O	O
in	in	O	O	O	O
unilateral	unilateral	O	O	O	O
6-hydroxydopamine	6-hydroxydopamine	CHEMICALS	O	OTHERS	I
(6-OHDA)-lesioned	(6-ohda)-lesioned	O	O	O	O
rats	rats	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
a	a	O	O	O	O
more	more	O	O	O	O
complex	complex	O	O	O	O
task	task	O	O	O	O
commonly	commonly	O	O	O	O
used	used	O	O	O	O
to	to	O	O	O	O
evaluate	evaluate	O	O	O	O
major	major	O	O	O	O
akinetic	akinetic	O	DISEASE	OTHERS	I
symptoms	symptoms	O	O	O	O
of	of	O	O	O	O
PD	pd	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
,	,	O	O	O	O
5	5	O	O	O	O
mg/kg	mg/kg	O	O	O	O
AMN082	amn082	O	O	OTHERS	I
reverses	reverses	O	O	O	O
the	the	O	O	O	O
increased	increased	O	O	O	O
reaction	reaction	O	O	O	O
time	time	O	O	O	O
to	to	O	O	O	O
respond	respond	O	O	O	O
to	to	O	O	O	O
a	a	O	O	O	O
cue	cue	O	O	O	O
of	of	O	O	O	O
bilateral	bilateral	O	O	O	O
6-OHDA-lesioned	6-ohda-lesioned	O	O	O	O
rats	rats	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
addition	addition	O	O	O	O
,	,	O	O	O	O
AMN082	amn082	O	O	OTHERS	I
reduces	reduces	O	O	O	O
the	the	O	O	O	O
duration	duration	O	O	O	O
of	of	O	O	O	O
haloperidol-induced	haloperidol-induced	O	O	O	O
catalepsy	catalepsy	O	DISEASE	OTHERS	I
in	in	O	O	O	O
a	a	O	O	O	O
mGlu7	mglu7	O	O	O	O
receptor-dependent	receptor-dependent	O	O	O	O
manner	manner	O	O	O	O
in	in	O	O	O	O
wild-type	wild-type	O	O	O	O
but	but	O	O	O	O
not	not	O	O	O	O
mGlu7	mglu7	O	O	O	O
receptor	receptor	O	O	O	O
knockout	knockout	O	O	O	O
mice	mice	O	O	O	O
.	.	O	O	O	O

Higher	higher	O	O	O	O
doses	doses	O	O	O	O
of	of	O	O	O	O
AMN082	amn082	O	O	OTHERS	I
(	(	O	O	O	O
10	10	O	O	O	O
and	and	O	O	O	O
20	20	O	O	O	O
mg/kg	mg/kg	O	O	O	O
p.o	p.o	O	O	O	O
.	.	O	O	O	O
)	)	O	O	O	O
have	have	O	O	O	O
no	no	O	O	O	O
effect	effect	O	O	O	O
on	on	O	O	O	O
the	the	O	O	O	O
same	same	O	O	O	O
models	models	O	O	O	O
of	of	O	O	O	O
PD	pd	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Overall	overall	O	O	O	O
these	these	O	O	O	O
findings	findings	O	O	O	O
suggest	suggest	O	O	O	O
that	that	O	O	O	O
mGlu7	mglu7	O	O	O	O
receptor	receptor	O	O	O	O
activation	activation	O	O	O	O
can	can	O	O	O	O
reverse	reverse	O	O	O	O
motor	motor	O	O	O	O
dysfunction	dysfunction	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
reduced	reduced	O	O	O	O
dopamine	dopamine	CHEMICALS	O	OTHERS	I
activity	activity	O	O	O	O
.	.	O	O	O	O

Selective	selective	O	O	O	O
ligands	ligands	O	O	O	O
of	of	O	O	O	O
mGlu7	mglu7	O	O	O	O
receptor	receptor	O	O	O	O
subtypes	subtypes	O	O	O	O
may	may	O	O	O	O
thus	thus	O	O	O	O
be	be	O	O	O	O
considered	considered	O	O	O	O
as	as	O	O	O	O
promising	promising	O	O	O	O
compounds	compounds	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
antiparkinsonian	antiparkinsonian	O	O	O	O
therapeutic	therapeutic	O	O	O	O
strategies	strategies	O	O	O	O
.	.	O	O	O	O

